Tuesday, 02 January 2024 12:17 GMT

Danske Bank Share Buy-Back Programme: Transactions In Week 39


(MENAFN- GlobeNewsWire - Nasdaq)


Company announcement no. 44 2025
Danske Bank
Bernstorffsgade 40
DK-1577 København V
Tel. + 45 33 44 00 00
29 September 2025
Page 1 of 1

Danske Bank share buy-back programme: transactions in week 39
On 7 February 2025, Danske Bank A/S announced a share buy-back programme for a total of DKK 5 billion, with a maximum of 45,000,000 shares, in the period from 10 February 2025 to 30 January 2026, at the latest, as described in company announcement no. 6 2025.
The Programme is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 of the European Parliament and Council of 16 April 2014 (the "Market Abuse Regulation") and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the "Safe Harbour Rules").
The following transactions on Nasdaq Copenhagen A/S were made under the share buy-back programme in week 39:


Number of shares VWAP DKK Gross value DKK
Accumulated, last announcement 12,740,348 243.7720 3,105,740,571
22 September 2025 62,327 268.0594 16,707,338
23 September 2025 5,000 273.9770 1,369,885
24 September 2025 5,000 271.3031 1,356,516
25 September 2025 165,000 269.8074 44,518,221
26 September 2025 23,500 272.8577 6,412,156
Total accumulated over week 39 260,827 269.7731 70,364,116
Total accumulated during the share buyback programme 13,001,175 244.2937 3,176,104,687



With the transactions stated above, the total accumulated number of own shares under the share buy-back programme corresponds to 1.557% of Danske Bank A/S' share capital.

Danske Bank
Contact: Claus Ingar Jensen, Head of Group Investor Relations, tel. +45 25 42 43 70

Attachment

  • Danske Bank Template Company announcement UK SBB announcement

MENAFN29092025004107003653ID1110123262

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Search